Literature DB >> 16951995

Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese.

Su Guan1, Min Huang, Xin Li, Xiao Chen, Eli Chan, Shu-Feng Zhou.   

Abstract

This study aimed to investigate the allele frequencies of CYP2B6 gene in 193 Han Chinese and compared with 91 Uygur Chinese. Five single nucleotide polymorphisms of CYP2B6, 64C > T, 516G > T, 777C > A, 785A > G and 1459C > T, were tested using the polymerase chain reaction-restriction fragment length polymorphism method. The allele frequencies for CYP2B6*2, CYP2B6*3, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*7 and CYP2B6*9 in Han and Uygur Chinese were 0.034 and 0.027, 0 and 0.011, 0.091 and 0.033, 0.003 and 0.049, 0.184 and 0.214, 0 and 0.022, and 0.018 and 0.044, respectively, with CYP2B6*4, CYP2B6*5, and CYP2B6*7 being significantly different between these two races (P < 0.05). CYP2B6*6 was the most prevalent allele among all detected variants in Han and Uygur Chinese. The most frequent genotypes were CYP2B6*1/CYP2B6*1 (50.8%), CYP2B6*1/CYP2B6*6 (24.4%), and CYP2B6*1/CYP2B6*4 (7.3%) in Han subjects, whereas the most frequent genotypes in Uygur subjects were CYP2B6*1/CYP2B6*1 (36.3%), CYP2B6*1/CYP2B6*6 (25.3%), CYP2B6*1/CYP2B6*5 (5.5%) and CYP2B6*6/CYP2B6*6 (5.5%). The frequencies of 64C > T mutation in Han and Uygur Chinese were significantly lower than that in American Caucasian (P < 0.05). These results indicate that there were marked ethnic differences in the mutant frequencies of CYP2B6 between Chinese and other ethnic groups. Further studies are warranted to explore the clinical impact of such ethnic differences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951995     DOI: 10.1007/s11095-006-9083-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

Authors:  Masahiro Hiratsuka; Yoh Takekuma; Naomi Endo; Kaori Narahara; Samar Ismail Hamdy; Yukinaga Kishikawa; Masaki Matsuura; Yasuyuki Agatsuma; Tomoko Inoue; Michinao Mizugaki
Journal:  Eur J Clin Pharmacol       Date:  2002-08-14       Impact factor: 2.953

2.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

3.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

4.  Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.

Authors:  Tanja Richter; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  Biochem Pharmacol       Date:  2004-12-15       Impact factor: 5.858

5.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

Review 6.  An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.

Authors:  Balram Chowbay; Shufeng Zhou; Edmund J D Lee
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

7.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:  David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

8.  The major phenobarbital-inducible cytochrome P-450 gene subfamily (P450IIB) mapped to the long arm of human chromosome 19.

Authors:  I Santisteban; S Povey; E A Shephard; I R Phillips
Journal:  Ann Hum Genet       Date:  1988-05       Impact factor: 1.670

9.  Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.

Authors:  T L Chen; J L Passos-Coelho; D A Noe; M J Kennedy; K C Black; O M Colvin; L B Grochow
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

10.  Inhibitory monoclonal antibody to human cytochrome P450 2B6.

Authors:  T J Yang; K W Krausz; M Shou; S K Yang; J T Buters; F J Gonzalez; H V Gelboin
Journal:  Biochem Pharmacol       Date:  1998-05-15       Impact factor: 5.858

View more
  12 in total

1.  Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.

Authors:  Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-06-09       Impact factor: 4.030

2.  Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Authors:  Monidarin Chou; Julie Bertrand; Olivier Segeral; Céline Verstuyft; Laurence Borand; Emmanuelle Comets; Clotilde Le Tiec; Laurent Becquemont; Vara Ouk; France Mentre; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

3.  In vitro-in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans.

Authors:  Miaoying Shi; Yumeng Dong; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2022-05-23       Impact factor: 6.168

Review 4.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

Review 5.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

6.  Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.

Authors:  Wenying Shu; Su Guan; Xiuyan Yang; Liuqin Liang; Jiali Li; Zhuojia Chen; Yu Zhang; Lingyan Chen; Xueding Wang; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

7.  Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Authors:  Xianmin Meng; Kang Yin; Jiangrong Wang; Ping Dong; Li Liu; Yinzhong Shen; Li Shen; Qing Ma; Hongzhou Lu; Weimin Cai
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 8.  Insights into CYP2B6-mediated drug-drug interactions.

Authors:  William D Hedrich; Hazem E Hassan; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

9.  The Prevalence of CYP2B6 Gene Polymorphisms in Malaria-endemic Population of Timor in East Nusa Tenggara Indonesia.

Authors:  Linawati Hananta; Indwiani Astuti; Ahmad Hamim Sadewa; Josephine Alice; Jontari Hutagalung
Journal:  Osong Public Health Res Perspect       Date:  2018-08

10.  Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Springerplus       Date:  2012-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.